First Citizens Bank & Trust Co. Acquires New Stake in Hims & Hers Health, Inc. $HIMS

First Citizens Bank & Trust Co. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 11,445 shares of the company’s stock, valued at approximately $571,000.

Several other institutional investors have also added to or reduced their stakes in HIMS. GAMMA Investing LLC lifted its position in Hims & Hers Health by 128.5% in the 1st quarter. GAMMA Investing LLC now owns 5,143 shares of the company’s stock valued at $152,000 after acquiring an additional 2,892 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Hims & Hers Health by 42.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 12,588 shares of the company’s stock valued at $372,000 after acquiring an additional 3,770 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at $257,000. Oppenheimer & Co. Inc. lifted its position in Hims & Hers Health by 8.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,289 shares of the company’s stock valued at $1,161,000 after acquiring an additional 3,079 shares in the last quarter. Finally, Perigon Wealth Management LLC lifted its position in Hims & Hers Health by 18.1% in the 1st quarter. Perigon Wealth Management LLC now owns 16,449 shares of the company’s stock valued at $486,000 after acquiring an additional 2,521 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Trading Up 0.8%

Shares of NYSE:HIMS opened at $48.86 on Friday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company’s 50-day moving average price is $51.14 and its two-hundred day moving average price is $49.66. The stock has a market capitalization of $11.04 billion, a PE ratio of 61.07, a price-to-earnings-growth ratio of 3.38 and a beta of 2.25. Hims & Hers Health, Inc. has a one year low of $18.33 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. KeyCorp began coverage on shares of Hims & Hers Health in a research report on Tuesday. They set a “sector weight” rating on the stock. Finally, Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Insider Activity

In other news, insider Michael Chi sold 900 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total value of $52,425.00. Following the sale, the insider directly owned 291,439 shares of the company’s stock, valued at approximately $16,976,321.75. This represents a 0.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $54.38, for a total transaction of $143,400.06. Following the completion of the sale, the insider directly owned 161,130 shares in the company, valued at approximately $8,762,249.40. The trade was a 1.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,432,206 shares of company stock valued at $74,248,448 in the last 90 days. 13.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.